BIOMAT Database Logo BIOMAT Database Logo

Purification and characterization of a new recombinant factor VIII (N8). 2010

L Thim, and B Vandahl, and J Karlsson, and N K Klausen, and J Pedersen, and T N Krogh, and M Kjalke, and J M Petersen, and L B Johnsen, and G Bolt, and P L Nørby, and T D Steenstrup
Biopharmaceutical Research Unit, Novo Nordisk A/S, Maaloev, Denmark. lth@novonordisk.com

A new recombinant factor VIII (FVIII), N8, has been produced in Chinese hamster ovary (CHO) cells. The molecule consists of a heavy chain of 88 kDa including a 21 amino acid residue truncated B-domain and a light chain of 79 kDa. The two chains are held together by non-covalent interactions. The four-step purification includes capture, affinity purification using a monoclonal recombinant antibody, anion exchange chromatography and gel filtration. The specific clotting activity of N8 was 8800-9800 IU mg(-1). Sequence and mass spectrometry analysis revealed two variants of the light chain, corresponding to two alternative N-terminal sequences also known from plasma FVIII. Two variants of the heavy chain are present in the purified product, namely with and without the B-domain linker attached. This linker is removed upon thrombin activation of N8 rendering an activated FVIII (FVIIIa) molecule similar to plasma FVIIIa. All six known tyrosine sulphations of FVIII were confirmed in N8. Two N-linked glycosylations are present in the A3 and C1 domain of the light chain and two in the A1 domain of the heavy chain. The majority of the N-linked glycans are sialylated bi-antennary structures. An O-glycosylation site is present in the B-domain linker region. This site was glycosylated with a doubly sialylated GalNAc-Gal structure in approximately 65% of the product. In conclusion, the present data show that N8 is a pure and well-characterized FVIII product with biochemical properties that equal other FVIII products.

UI MeSH Term Description Entries
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D002852 Chromatography, Ion Exchange Separation technique in which the stationary phase consists of ion exchange resins. The resins contain loosely held small ions that easily exchange places with other small ions of like charge present in solutions washed over the resins. Chromatography, Ion-Exchange,Ion-Exchange Chromatography,Chromatographies, Ion Exchange,Chromatographies, Ion-Exchange,Ion Exchange Chromatographies,Ion Exchange Chromatography,Ion-Exchange Chromatographies
D005169 Factor VIII Factor VIII of blood coagulation. Antihemophilic factor that is part of the factor VIII/von Willebrand factor complex. Factor VIII is produced in the liver and acts in the intrinsic pathway of blood coagulation. It serves as a cofactor in factor X activation and this action is markedly enhanced by small amounts of thrombin. Coagulation Factor VIII,Factor VIII Clotting Antigen,Factor VIII Coagulant Antigen,Factor VIII Procoagulant Activity,Thromboplastinogen,Blood Coagulation Factor VIII,F VIII-C,Factor 8,Factor 8 C,Factor Eight,Factor VIIIC,Hyate-C,Hyatt-C,F VIII C,Hyate C,HyateC,Hyatt C,HyattC
D006023 Glycoproteins Conjugated protein-carbohydrate compounds including MUCINS; mucoid, and AMYLOID glycoproteins. C-Glycosylated Proteins,Glycosylated Protein,Glycosylated Proteins,N-Glycosylated Proteins,O-Glycosylated Proteins,Glycoprotein,Neoglycoproteins,Protein, Glycosylated,Proteins, C-Glycosylated,Proteins, Glycosylated,Proteins, N-Glycosylated,Proteins, O-Glycosylated
D006224 Cricetinae A subfamily in the family MURIDAE, comprising the hamsters. Four of the more common genera are Cricetus, CRICETULUS; MESOCRICETUS; and PHODOPUS. Cricetus,Hamsters,Hamster
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014357 Trypsin A serine endopeptidase that is formed from TRYPSINOGEN in the pancreas. It is converted into its active form by ENTEROPEPTIDASE in the small intestine. It catalyzes hydrolysis of the carboxyl group of either arginine or lysine. EC 3.4.21.4. Tripcellim,Trypure,beta-Trypsin,beta Trypsin
D015153 Blotting, Western Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes. Immunoblotting, Western,Western Blotting,Western Immunoblotting,Blot, Western,Immunoblot, Western,Western Blot,Western Immunoblot,Blots, Western,Blottings, Western,Immunoblots, Western,Immunoblottings, Western,Western Blots,Western Blottings,Western Immunoblots,Western Immunoblottings

Related Publications

L Thim, and B Vandahl, and J Karlsson, and N K Klausen, and J Pedersen, and T N Krogh, and M Kjalke, and J M Petersen, and L B Johnsen, and G Bolt, and P L Nørby, and T D Steenstrup
N8-GP: A new extended half-life recombinant factor VIII product for hemophilia A.
September 2020, Journal of thrombosis and haemostasis : JTH,
L Thim, and B Vandahl, and J Karlsson, and N K Klausen, and J Pedersen, and T N Krogh, and M Kjalke, and J M Petersen, and L B Johnsen, and G Bolt, and P L Nørby, and T D Steenstrup
Characterization of recombinant human factor VIII.
March 1987, The Journal of biological chemistry,
L Thim, and B Vandahl, and J Karlsson, and N K Klausen, and J Pedersen, and T N Krogh, and M Kjalke, and J M Petersen, and L B Johnsen, and G Bolt, and P L Nørby, and T D Steenstrup
Production and characterization of recombinant factor VIII.
April 1991, Seminars in hematology,
L Thim, and B Vandahl, and J Karlsson, and N K Klausen, and J Pedersen, and T N Krogh, and M Kjalke, and J M Petersen, and L B Johnsen, and G Bolt, and P L Nørby, and T D Steenstrup
Characterization of recombinant factor VIII and a recombinant factor VIII deletion mutant using a rabbit immunogenicity model system.
October 1990, Blood,
L Thim, and B Vandahl, and J Karlsson, and N K Klausen, and J Pedersen, and T N Krogh, and M Kjalke, and J M Petersen, and L B Johnsen, and G Bolt, and P L Nørby, and T D Steenstrup
Structural and functional characterization of Factor VIII-delta II, a new recombinant Factor VIII lacking most of the B-domain.
July 1991, The Biochemical journal,
L Thim, and B Vandahl, and J Karlsson, and N K Klausen, and J Pedersen, and T N Krogh, and M Kjalke, and J M Petersen, and L B Johnsen, and G Bolt, and P L Nørby, and T D Steenstrup
Expression and characterization of recombinant murine factor VIII.
September 2002, Thrombosis and haemostasis,
L Thim, and B Vandahl, and J Karlsson, and N K Klausen, and J Pedersen, and T N Krogh, and M Kjalke, and J M Petersen, and L B Johnsen, and G Bolt, and P L Nørby, and T D Steenstrup
Human factor VIII: purification from commercial factor VIII concentrate, characterization, identification and radiolabeling.
October 1986, Biochimica et biophysica acta,
L Thim, and B Vandahl, and J Karlsson, and N K Klausen, and J Pedersen, and T N Krogh, and M Kjalke, and J M Petersen, and L B Johnsen, and G Bolt, and P L Nørby, and T D Steenstrup
The purification of factor VIII and the characterization of the human factor VIII gene.
April 1995, Haemophilia : the official journal of the World Federation of Hemophilia,
L Thim, and B Vandahl, and J Karlsson, and N K Klausen, and J Pedersen, and T N Krogh, and M Kjalke, and J M Petersen, and L B Johnsen, and G Bolt, and P L Nørby, and T D Steenstrup
Functional characteristics of N8, a new recombinant FVIII.
November 2010, Haemophilia : the official journal of the World Federation of Hemophilia,
L Thim, and B Vandahl, and J Karlsson, and N K Klausen, and J Pedersen, and T N Krogh, and M Kjalke, and J M Petersen, and L B Johnsen, and G Bolt, and P L Nørby, and T D Steenstrup
Development and characterization of recombinant ovine coagulation factor VIII.
January 2012, PloS one,
Copied contents to your clipboard!